ANTITUMOR EFFICACY OF LIPOSOMAL DOXORUBICIN HYDROCHLORIDE IN COMBINATION WITH TAMOXIFEN. EXPERIMENTAL STUDY

In this paper we evaluated the effectiveness of adjuvant chemotherapy in animals (n=30), which created a model of cancerogenesis. We created 3 equal studies: the 1st group control (n=10) - animals were monitored without treatment; the 2nd group (n=10) - animals received adjuvant therapy with a combination of drugs: liposomal doxorubicin hydrochloride+tamoxifen;the 3rd group (n=10) - animals received adjuvant therapy in a combination of doxorubicin hydrochloride (non-liposomal)+tamoxifen. All animals were monitored for a total of 30 days. As a result, the volume of the tumor in the group of animals treated with liposomal doxorubicin hydrochloride was almost 3 times less than in the control group, and 2 times less than in the rats treated with simple doxorubicin. We also recorded a significantly lower number of lung metastases in animals of the second group compared to other groups. CONCLUSION. Treatment of Walker 256 tumors with liposomal doxorubicin showed better efficacy and safety compared to non-liposomal doxorubicin.